Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma

Authors

Matthew J. Maurer, Mayo Clinic
Brad S. Kahl, Washington University School of Medicine in St. Louis
et al.

Journal

Haematologica

Publication Date

7-1-2024

Volume

109

Issue

7

First Page

2177

Last Page

2185

Document Type

Open Access Publication

DOI

10.3324/haematol.2023.283737

Rights and Permissions

Maurer MJ, Casulo C, Larson MC, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan JR, Link BK, Flowers CR. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma. Haematologica. 2024 Jul 1;109(7):2177-2185. doi: 10.3324/haematol.2023.283737. ©2024 Ferrata Storti Foundation Published under a CC BY-NC license.

Recommended Citation

Maurer, Matthew J.; Kahl, Brad S.; and et al., "Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma." Haematologica. 109, 7. 2177 - 2185. (2024).
https://digitalcommons.wustl.edu/oa_4/3970

Additional Links

Supplemental material is available for this article at publisher site.